Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Cipla
Dow
Boehringer Ingelheim
UBS
Chubb
Fuji
Argus Health
Federal Trade Commission
McKesson

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,635,707

« Back to Dashboard

Which drugs does patent 7,635,707 protect, and when does it expire?

Patent 7,635,707 protects ESBRIET and is included in two NDAs.

This patent has fifty-three patent family members in thirty-five countries.
Summary for Patent: 7,635,707
Title:Pirfenidone treatment for patients with atypical liver function
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Inventor(s): Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Mateo, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:12/553,292
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,635,707

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genentech Inc ESBRIET pirfenidone CAPSULE;ORAL 022535-001 Oct 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-001 Jan 11, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-003 Jan 11, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,635,707

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,566,729 Modifying pirfenidone treatment for patients with atypical liver function ➤ Subscribe
8,592,462 Pirfenidone treatment for patients with atypical liver function ➤ Subscribe
8,609,701 Pirfenidone treatment for patients with atypical liver function ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,635,707

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Tunisia 2011000217 ➤ Subscribe
El Salvador 2011003897 ➤ Subscribe
San Marino T201500088 ➤ Subscribe
San Marino T201100030 ➤ Subscribe
Slovenia 2343070 ➤ Subscribe
Slovenia 2191831 ➤ Subscribe
Serbia 53721 ➤ Subscribe
Serbia 51787 ➤ Subscribe
Portugal 2343070 ➤ Subscribe
Portugal 2191831 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
UBS
Cantor Fitzgerald
Cipla
Medtronic
Healthtrust
Chinese Patent Office
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot